News Mavenclad May Be Added to RRMS Treatments on Quebec’s Public Health Plan Mavenclad May Be Added to RRMS Treatments on Quebec’s Public Health Plan by Marisa Wexler, MS | February 10, 2020 Share this article: Share article via email Copy article link Niyazz/Shutterstock The agency in charge of health and social services for Quebec, known as theĀ Institut national d’excellence en santĆ© et en services sociaux (INESSS), is recommending thatĀ Mavenclad (cladribine) be offered at discount to adults with relapsing-remitting multiple sclerosis (RRMS) enrolled in the province’s health system. INESSS’ opinions are taken by the minister for that agency, who makes the final decision on listing prescription services and medications in Quebec’s public health plan. Mavenclad, developed and marketed by EMD Serono (Merck KGaA outside of the U.S. and Canada), is a disease-modifying and short-course oral treatment that works to reduce the number of immune cells in circulation, limiting the inflammation that causes nervous system damage in MS. Data from clinical trials support that Mavenclad can significantly lower relapse rates and the risk of disability progression in people with RRMS. The therapy was first approved to treat RRMS by Health Canada in December 2017. The European Commission approved it earlier that year for highly active relapsing forms of MS, and in 2019 the U.S. Food and Drug Administration (FDA) approved it for both RRMS and active secondary progressive multiple sclerosis (SPMS). “We are delighted with the positive recommendation from INESSS, which recognizes the therapeutic value of Mavenclad and the need for this treatment option for eligible patients who live with RRMS,” Gaby Murphy, president and managing director of EMD Serono, Canada, said in aĀ press release. “We welcome this as an important step to ensure broader and equitable access to Mavenclad in the province of Quebec,” Murphy added. EMD Serono will now work with theĀ MinistĆØre de la SantĆ© et des Services sociauxĀ to add Mavenclad to theĀ RĆ©gie de l’assurance maladie du QuĆ©becĀ (RAMQ)Ā List of Medications. The purpose of this list is ” to ensure that all persons in QuĆ©bec have reasonable and fair access to the medication required by their state of health,” with out-of-pocket costs tailored to a family’s “economic situation,” LĆ©gis QuĆ©bec reports. The therapy is covered by most private insurance plans. “Some 20,000 people inĀ Quebec alone are living with MS, and the INESSS recommendation for Mavenclad is great news for patients,” saidĀ Louis Adam, executive director of the QuebecĀ and Atlantic Division of the MS Society ofĀ Canada. “Having access to new and innovative treatment options is important for people living with MS in the province ofĀ Quebec, and we are delighted by this positive step forward.” Canada has one of the highest rates of MS in the world, with an estimated 1 in every 385 people in the country having the disease, the MS Society ofĀ Canada reports. Print This Page About the Author Marisa Wexler, MS Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America. Tags Canada, Cladribine, EMD Serono, Mavenclad, RRMS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients